Q2 Earnings Estimate for IDYA Issued By Wedbush

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Equities research analysts at Wedbush issued their Q2 2025 earnings estimates for shares of IDEAYA Biosciences in a note issued to investors on Tuesday, May 6th. Wedbush analyst R. Driscoll expects that the company will earn ($0.88) per share for the quarter. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Wedbush also issued estimates for IDEAYA Biosciences’ Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($3.69) EPS, FY2026 earnings at ($4.08) EPS, FY2027 earnings at ($3.82) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at $0.53 EPS.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). During the same period in the previous year, the firm posted ($0.53) earnings per share.

Other research analysts have also recently issued reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Stephens restated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.58.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $17.37 on Friday. The business’s fifty day moving average is $17.74 and its 200-day moving average is $22.64. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -5.26 and a beta of 0.26. IDEAYA Biosciences has a one year low of $13.45 and a one year high of $44.42.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC raised its position in shares of IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company’s stock worth $5,739,000 after buying an additional 118,438 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of IDEAYA Biosciences by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company’s stock valued at $2,527,000 after acquiring an additional 12,029 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company’s stock valued at $475,000 after acquiring an additional 15,089 shares during the last quarter. KBC Group NV grew its holdings in shares of IDEAYA Biosciences by 84.6% during the fourth quarter. KBC Group NV now owns 4,197 shares of the company’s stock worth $108,000 after purchasing an additional 1,923 shares in the last quarter. Finally, R Squared Ltd bought a new position in shares of IDEAYA Biosciences in the fourth quarter worth approximately $35,000. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.